Life sciences firm Sartorius is introducing an integrated system for the production and quality control (QC) of autologous cell therapies, addressing ‘structural manufacturing bottlenecks’ that ‘limit scalability and patient access to transformative treatments’ such as CAR-T therapies.
The modular Eveo Cell Therapy Platform, per Sartorius, strengthens the company’s position in the dynamic advanced therapies market.
It has sought to develop a solution for autologous cell therapies that addresses the constraints of centralised, purpose-built facilities. Such facilities require significant greenfield investment, staff recruitment, training and multi-year build-up phases, with around 60% of regulatory disruptions in cell therapies said to be caused by manufacturing and process-related issues.
With the new Eveo system, Sartorius says cell selection, activation, gene modification, expansion, wash, concentration and final formulation are integrated into a closed system. The system’s compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralised and decentralised manufacturing models, per Sartorius.
Sartorius has collaborated with ElevateBio, a leading cell therapy CDMO, amongst other partners, to test out the Eveo platform. In a successful pilot, the system is said to have performed in line with design expectations. Due to its multi-parallel configuration, a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches. Assuming a manufacturing time of around seven days per batch and 50 production weeks per year, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses – an almost fourfold increase. Financial modelling suggests the platform can reduce manufacturing costs by around 90%, while Sartorius is also confident the platform will ease pain points in QC.
“Cell therapies are redefining medical possibilities,” said René Fáber, member of the Executive Board at Sartorius. “Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on. By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients.”
Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its manufacturing customers.
